Theravance Biopharma/$TBPH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Theravance Biopharma
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
Ticker
$TBPH
Sector
Primary listing
Employees
90
Headquarters
Website
TBPH Metrics
BasicAdvanced
$873m
7.62
$2.21
0.19
-
Price and volume
Market cap
$873m
Beta
0.19
52-week high
$21.03
52-week low
$10.82
Average daily volume
841k
Financial strength
Current ratio
13.143
Quick ratio
12.911
Long term debt to equity
10.238
Total debt to equity
10.238
Interest coverage (TTM)
2.74%
Profitability
EBITDA (TTM)
6.576
Gross margin (TTM)
71.04%
Net profit margin (TTM)
104.34%
Operating margin (TTM)
4.54%
Effective tax rate (TTM)
16.34%
Revenue per employee (TTM)
$1,220,000
Management effectiveness
Return on assets (TTM)
0.76%
Return on equity (TTM)
50.17%
Valuation
Price to earnings (TTM)
7.621
Price to revenue (TTM)
7.784
Price to book
2.99
Price to tangible book (TTM)
2.99
Price to free cash flow (TTM)
3.18
Free cash flow yield (TTM)
31.45%
Free cash flow per share (TTM)
5.3
Growth
Revenue change (TTM)
68.20%
Earnings per share change (TTM)
-286.49%
3-year revenue growth (CAGR)
31.24%
10-year revenue growth (CAGR)
10.59%
3-year earnings per share growth (CAGR)
-43.75%
10-year earnings per share growth (CAGR)
-8.05%
What the Analysts think about TBPH
Analyst ratings (Buy, Hold, Sell) for Theravance Biopharma stock.
TBPH Financial Performance
Revenues and expenses
TBPH Earnings Performance
Company profitability
TBPH News
AllArticlesVideos
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders
Business Wire·1 month ago
Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition
Benzinga·1 month ago
Zymeworks strikes $929 million deal for Theravance Biopharma
Reuters·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.